Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

BACKGROUND: Sequential inhibition of the vascular endothelial growth factor (VEGF) pathway with sorafenib could be useful for patients with metastatic renal cell carcinoma (RCC). Our aim was to determine the activity and tolerability of sorafenib as a second-line therapy in advanced RCC initially tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Aguilar, Ana Elena, Núñez-López, Haidé, Ramirez-Sandoval, Juan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786959/
https://www.ncbi.nlm.nih.gov/pubmed/33402115
http://dx.doi.org/10.1186/s12885-020-07720-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786959/
https://www.ncbi.nlm.nih.gov/pubmed/33402115
http://dx.doi.org/10.1186/s12885-020-07720-5

Ejemplares similares